Immediate outcomes of eptifibatide therapy during intracoronary stent implantation

Shariati, Hooman; Sanei, Hamid; Pourmoghadas, Ali; Salehizadeh, Leila; Amirpour, Afshin

doi:10.4103/2277-9175.196831

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLR was defined as repeat PCI for restenosis at the lesion treated during index PCI. Although this finding is not consistent with the study of Shariati et al [ 13 ], it can be justified considering the mechanism of effect of Eptifibatide. Eptifibatide prevents the binding of fibrinogen to receptor and reduces the activation of prothrombin replication factors.…”

Section: Discussioncontrasting

confidence: 99%

“…To our knowledge, few clinical trials have been conducted on the effect of Eptifibatide in patients undergoing PPCI due to STEMI. A retrospective study that was conducted between 2000 and 2009 in the United States and showed that the administration of Eptifibatide reduces mortality in STEMI patients who undergo PPCI [ 25 ], while the study by Le May et al, and the study of Shariati et al, showed that the administration of this drug does not reduce MACE (combined mortality and recurrent myocardial infarction) [ 13 , 26 ]. These observations, however, have not been fully supported by a retrospective analysis of clinical outcomes in the ESPRIT trial, accepting that this was not a primary PCI study and not everyone in the preloading group received the 600 mg dose of Clopidogrel, the study demonstrated that the efficacy of Eptifibatide was maintained irrespective of Thienopyridine preloading.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

et al. 2023

View full text Add to dashboard Cite

Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion. So far, few studies have investigated the effect of maintenance dose of Eptifibatide (glycoprotein IIb/IIIa inhibitor) in STEMI patients who underwent primary percutaneous coronary intervention (PPCI). Therefore, in this study, we investigated the effect of maintenance dose of Eptifibatide in patients with STEMI who underwent PPCI. 264 patients who had acute chest pain suggestive of STEMI were entered in the study. All patients received the same dose of bolus dose of Eptifibatide in the cardiac catheterization laboratory. Then the patients were randomly divided into two groups, one group (n = 147) received a maintenance dose of intravenous Eptifibatide (infusion of 2 μg/kg/min) and the other group (n = 117) did not receive this treatment. Standard medical treatment of STEMI after PPCI was performed based on guidelines and the same in both groups. All patients were evaluated 1, 2, and 3 months after the start of treatment in terms of predicted outcomes. Results The occurrence of 3-month major adverse cardiovascular events (MACE) between the case and control groups did not have a statistically significant difference (28.6% versus 35.0%; P value: 0.286). Also, investigations showed that the rate of re-infarction (P value: 0.024) and target lesion revascularization (P value: 0.003) was significantly lower in the group that received Eptifibatide infusion. Conclusions Eptifibatide maintenance dose infusion in patients who undergo PPCI in the context of STEMI, does not significantly reduce MACE, although it does significantly reduce re-infarction and target lesion revascularization. It also does not increase the risk of bleeding and cerebrovascular events.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Previously, eptifibatide was mainly used with bolus dose following infusion which showed significantly less complication 30 days after intervention [ 4 , 6 - 8 ], but it accompanies with the increased risk of bleeding [ 4 ]. Other studies have shown that single bolus dose only can be as effective as infusion by improving long-term survival [ 9 - 11 ].…”

Section: Introductionmentioning

confidence: 99%

Eptifibatide Bolus Dose During Elective Percutaneous Coronary Intervention

et al. 2018

View full text Add to dashboard Cite

BackgroundEptifibatide is a platelet glycoprotein IIb/IIIa receptor antagonist used for the prevention of cardiac ischemic complications of percutaneous coronary intervention (PCI). Eptifibatide has been used with bolus dose only or bolus plus infusion in patients undergoing PCI which have shown less complications, but the risk of bleeding has been increased. We aimed to compare the outcome and bleeding rate of bolus dose alone or plus infusion in elective PCI.MethodsIn this quasi-experimental study, we compared the outcome of elective PCI following single bolus dose intracoronary (41 patients) or bolus plus intravenous infusion (19 patients) of eptifibatide. In-hospital and follow-up major adverse cardiac events (MACEs) and bleeding rate were recorded and evaluated between groups.ResultsBoth groups were comparable regarding baseline findings. Bolus only compared to bolus plus infusion group had lower in-hospital (19.5% vs. 31.6%) and follow-up MACE (15.4% vs. 17.6%), lower bleeding in-hospital (14.6% vs. 21.1%) and follow-up (2.4% vs. 5.3%) as well as lower mortality rate in hospital (4.9% vs. 15.8%), but higher follow-up mortality (10.3% vs. 0), but the difference was not significant.ConclusionsWe observed no significant difference regarding bleeding or MACE between intracoronary bolus infusion and bolus plus intravenous infusion of eptifibatide. It seems intracoronary bolus infusion of eptifibatide due to use of lower doses is a better choice in elective PCI to prevent post-PCI MACE.

show abstract